Ethypharm, Inc.

Laboratoires Des Produits Ethiques Ethypharm

Debregeas Et Associes Pharma

Laboratoires Des Products Ethiques Ethypharm

Sunfone Electronics Co.

Laboratoire Des Produits Ethiques Ethypharm

Laboratories Des Produits Ethiques Ethypharim

Laboratories Des Produits Ethiques Ethypharm

Pascal Suplie

Pascal Oury

Patrice Debregeas

Christophe Lebon

G&eacute;rard Leduc

Bruno Criere

Philippe Chenevier

George Bobotas

Gerard Leduc

Keith S Rotenberg

Dominique Marechal

Edouard Gendrot

Frantz Deschamps

Fabrice Leboeuf

Jennifer Jung

Nourredine Nouri

David Olivier Paul

Emmanuel Guerin

Sandrine Salle

Sylvie Lecoustey

Philippe Vivet

Gérard Leduc

Immediate release, oral, pharmaceutical formulation comprising nalbuphine or a pharmaceutically acceptable salt thereof, and at least one hydrophilic granulation carrier, one hydrophilic binder and one lubricant.

Formulations containing nalbuphine and uses thereof

A granule including a solid core on which is supported an active ingredient, said active ingredient being selected from gamma-hydroxybutric acid or one of its pharmaceutically acceptable salts, said granule further including, supported on said solid core, one or more compounds which may generate gas evolvement, one or more diluents, said granule being in that it is coated with a membrane, and in that the solid core represents from 15% to 50% by weight based on the total weight of the granule.

Gamma hydroxybutyric acid granules

The present invention relates to a novel method for obtaining a pharmaceutical composition based on modafinil. This method consists of solubilizing S modafinil in a fluid in the supercritical state and then after expansion of said fluid, recovering S modafinil by causing it to be absorbed at the surface by a support appearing as granules. Said fluid may be COor another solvent and the support, anhydrous lactose or mannitol. Application of the pharmaceutical composition in the cases when increased short term alertness and over a short period is required for the consumer of the pharmaceutical composition.

Process for obtaining a modafinil-based pharmaceutical composition, resulting pharmaceutical composition and use thereof

Granules having a solid core on which an active ingredient is supported, the core being chosen preferably from among insoluble supports, the granules also having, supported on said the core, the following compounds: one or more coloring agents, one or more metallic pigments, one or more gas-releasing compounds, and optionally one or more embittering agents.

Pharmaceutical formulations to prevent the misuse of medicinal drugs

The present invention relates to a floating granule comprising a solid core, on which an active ingredient is supported and also comprising a compound which is capable of generating a gas discharge which is constituted by an alkaline agent, characterized in that it does not comprise an acid agent which is capable of generating a gas discharge.

Floating microgranules

The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables to enhance the bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.

Pharmaceutical composition containing fenofibrate and method for the preparation thereof

The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.

The present invention relates to a granule of gamma-hydroxybutyric acid or of one of its pharmaceutically acceptable salts, characterized in that it comprises a solid core on which the gamma-hydroxybutyric acid or one of its salts is supported.

Composition based on gamma-hydroxybutyric acid

Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions.

A pharmaceutical formulation of a gastric proton pump inhibitor, with the exception of omeprazole, is disclosed. The formulation is in the form of microgranules insoluble in gastric fluid having improved stability over time. The formulation comprises several hydrophobic substances chosen in order to increase the stability of the active principle while obtaining the desired dissolution profile.

Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations

Pharmaceutical composition containing fenofibrate and the preparation method

The present invention concerns a novel sustained-release oral formulation of morphine sulphate in the form of microgranules. Each microgranule comprises a neutral support grain coated with an active layer and with a sustained-release layer, characterized in that the sustained-release layer contains a copolymer of methacrylic acid and of methyl methacrylate ester, the relative proportion of the free carboxyl groups and of the ester groups of which is equal to 0.5 approximately, and a silica exhibiting a hydrophobic character. The present invention also concerns a process for preparing these microgranules which is carried out entirely in aqueous medium by emplacing on neutral support grains.

Morphine sulphate microgranules, method for preparing same and compositions containing same

The invention relates to a drinkable ibuprofen solution wherein the soluble fraction of the active ingredient contained therein is less than 10% by weight in relation to the weight of the suspension.

Drinkable ibuprofen pharmaceutical suspension

Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).

Growing community of inventors

Montaure, France

Pascal Suplie